Friday was the last options expiration of the year - unsurprisingly GERN was below $1.50
It’s a question of if not when Imetelstat succeeds to regulatory approval. The Mayo Pilot trial delivered CRs in 2013. The mid stage trials had a terrible trial design imo, and yet Imetelstat showed remarkable results. The late stage trials will succeed as well, and a ton of top notch talent arrived at the company to ensure success and world class standards for manufacturing and delivery upon regulatory approval.
When not if. Shorts (~40 Million still wow!) and options traders have known this, and have known the when was quite a ways away. In my opinion, success still is a ways away, however I a